Population Pharmacokinetic/Pharmacodynamic Modeling of Tacrolimus in Renal Transplant Recipients: Impact of CYP3A5 Genotype and Wuzhi Capsule Co-Medication
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Population pharmacokinetic/pharmacodynamic (PK/PD) models reveal optimal tacrolimus dosing strategies for renal transplant recipients, considering CYP3A5 genotype and Wuzhi capsule use to minimize adverse effects like kidney injury.
Area Of Science
- Pharmacology
- Nephrology
- Transplantation Medicine
Background
- Tacrolimus is essential for preventing renal transplant rejection but carries risks of adverse reactions, including posttransplantation diabetes mellitus and renal injury.
- Understanding the relationship between tacrolimus dosage, exposure, and adverse effects is critical for improving patient outcomes in renal transplant recipients.
Purpose Of The Study
- To develop population pharmacokinetic/pharmacodynamic (PK/PD) models to analyze tacrolimus dose, exposure, and adverse event relationships in renal transplant recipients.
- To identify key covariates influencing tacrolimus pharmacokinetics and pharmacodynamics for personalized dosing.
Main Methods
- Developed population PK/PD models using clinical data from renal transplant recipients.
- Investigated covariates including demographics, CYP3A5 genotype, laboratory results, and co-medications.
- Performed dose simulations based on established PK/PD models.
Main Results
- CYP3A5 genotype, Wuzhi capsule use, and postoperative days significantly impacted tacrolimus clearance.
- Tacrolimus trough concentration (C0) correlated with fasting plasma glucose (FPG) and estimated glomerular filtration rate (eGFR).
- Simulations indicated specific initial dosing requirements for CYP3A5*1 carriers and cautioned against Wuzhi capsule use in CYP3A5*3/*3 genotype patients due to kidney damage risk.
Conclusions
- Population PK/PD models effectively quantify the link between tacrolimus dosing, exposure, and adverse effects in renal transplant patients.
- These models provide a valuable reference for optimizing individualized tacrolimus dosage regimens.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...